Jane Street Group, LLC Intellia Therapeutics, Inc. Call Options Transaction History

Jane Street Group, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $1.4 Million - $1.94 Million	70,800 New	70,800 $1.45 Million
Q1 2022 May 17, 2022	SELL	$58.27 - $118.99 $786,645 - $1.61 Million	-13,500 Reduced 14.02%	82,800 $6.02 Million
Q4 2021 Feb 15, 2022	SELL	$100.76 - $138.36 $30,228 - $41,508	-300 Reduced 0.31%	96,300 $11.4 Million
Q3 2021 Nov 16, 2021	SELL	$132.37 - $176.78 $34.8 Million - $46.5 Million	-263,100 Reduced 73.14%	96,600 $13 Million
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $16.2 Million - $43.2 Million	266,900 Added 287.61%	359,700 $58.2 Million
Q1 2021 May 18, 2021	SELL	$46.59 - $83.68 $2 Million - $3.59 Million	-42,900 Reduced 31.61%	92,800 $7.45 Million
Q4 2020 Feb 17, 2021	BUY	$18.83 - $63.53 $1.06 Million - $3.58 Million	56,400 Added 71.12%	135,700 $7.38 Million
Q2 2020 Aug 17, 2020	BUY	$11.14 - $22.87 $883,402 - $1.81 Million	79,300 New	79,300 $1.67 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $775M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.